0001209191-22-016242.txt : 20220304
0001209191-22-016242.hdr.sgml : 20220304
20220304162505
ACCESSION NUMBER: 0001209191-22-016242
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220303
FILED AS OF DATE: 20220304
DATE AS OF CHANGE: 20220304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ASADORIAN RAFFI
CENTRAL INDEX KEY: 0001628970
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35068
FILM NUMBER: 22714416
MAIL ADDRESS:
STREET 1: C/O ACELRX PHARMACEUTICALS, INC.
STREET 2: 351 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001427925
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25821 INDUSTRIAL BOULEVARD
STREET 2: SUITE 400
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: 650-216-3500
MAIL ADDRESS:
STREET 1: 25821 INDUSTRIAL BOULEVARD
STREET 2: SUITE 400
CITY: HAYWARD
STATE: CA
ZIP: 94545
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-03
0
0001427925
ACELRX PHARMACEUTICALS INC
ACRX
0001628970
ASADORIAN RAFFI
C/O ACELRX PHARMACEUTICALS, INC.
25821 INDUSTRIAL BLVD., SUITE 400
HAYWARD
CA
94545
0
1
0
0
Chief Financial Officer
Common Stock
2022-03-03
4
F
0
7923
0.4068
D
364205
D
Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Balance includes non-reportable acquisition of 4,040 shares of Common Stock through the Company's Employee Stock Purchase Plan.
On February 14, 2022, the reporting person filed a Form 4 which inadvertently under-reported his holdings in the Issuer by 8 shares. In addition to reporting the current transactions, this Form 4 serves to correct the reporting person's holdings in the Issuer.
/s/ Martha Adler, Attorney-In-Fact
2022-03-04